cyclopharm

27 January 2026

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Technegas® Recognised as Preferred Agent for Clinical Use in Key US and International Lung Imaging Guideline

Cyclopharm today notes a significant new draft guideline for US clinical practice released by the US peak nuclear medicine imaging body which explicitly recognises its flagship functional lung imaging product Technegas® as a preferred ventilation agent.

Released for public consultation, the Procedure Standard and Guideline for Ventilation-Perfusion (V/Q) Pulmonary Scintigraphy[1] recognises Technegas for clinical use in the US, stating that "for most conditions, including the assessment of pulmonary embolism, technetium agents are typically used, with Technegas generally preferred when available."

The Procedure Standard and Guideline has been developed by a multinational expert panel, primarily for both the US Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American College of Nuclear Medicine (ACNM) in collaboration with the European Association of Nuclear Medicine (EANM) and experts from Australia and Canada.

US clinical guidance recognition is a material inflection point for Technegas in the US market. The draft guideline, which is stated to have already undergone a "thorough clinical consensus process and extensive review", has been released as a public consultation draft and will be refined for factual variations following feedback from the global nuclear medicine community. Final publication is expected in the coming months.

The Procedure Standard and Guideline outlines practices for performing and interpreting lung imaging studies, featuring Technegas in its introduction as a clinical advancement, "which has enhanced the diagnostic accuracy and clinical utility of lung scintigraphy".

Cyclopharm expects Technegas' inclusion and positioning in the document will drive accelerated clinical demand in the US. The guideline supports broader institutional adoption, increased utilisation and more rapid integration of Technegas into standard clinical workflows across US hospitals and health systems.

The Procedure Standard and Guideline is the first comprehensive update to US-aligned nuclear medicine lung imaging guidance since 2012 and reflects more than a decade of international clinical, technological and evidentiary progress in lung imaging.

[1] https://snmmi.org/Web/Clinical-Practice/Procedure-Standards/For-Comment/SNMMI%20EANM%20ACNM%20Guideline%20for%20Ventilation-Perfusion%20Pulmonary%20Scintigraphy

Cyclopharm CEO James McBrayer said, “This guideline provides clinical practitioners with evidence-based recommendations for conducting and interpreting lung imaging.”

“Guidelines developed through international multi-society collaboration are uncommon and carry a unique level of authority within clinical practice. When such consensus guidelines are established, they represent a foundational reference point for clinicians and institutions. When combined with peer-reviewed clinical evidence, these guidelines sit at the top of the hierarchy of evidence required to enable durable changes in clinical behaviour, hospital procurement and reimbursement decisions,” Mr McBrayer said.

Beyond pulmonary embolism, the draft guideline highlights the expanding clinical role of SPECT and SPECT/CT imaging with Technegas across multiple indications, including chronic thromboembolic pulmonary hypertension, COPD, asthma, post-PE follow-up, lung transplantation, radiotherapy planning and regional lung function assessment. The guideline notes that contemporary lung scintigraphy now extends into other clinical applications, enabled by advanced imaging techniques to include AI and functional ventilation agents like Technegas.

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited
Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas
Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being utilised in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.